Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
United States (U.S.) Duty-Included Shipping For orders shipping to the United States, required U.S
Consistency may be more important than time of the day, though
This dual action reduces appetite and slows gastric emptying (the rate at which food leaves your stomach) more effectively than medications that mimic GLP-1 alone
Mechanism Difference: Tirzepatide (Zepbound/Mounjaro): Dual GIP/GLP-1 receptor agonist Semaglutide (Wegovy/Ozempic): GLP-1 receptor agonist only Published Clinical Trial Data (Separate Studies): Tirzepatide (SURMOUNT-1): 16.0% to 22.5% mean weight loss at 72 weeks depending on dose Semaglutide (STEP trials): Approximately 15% mean weight loss at 68 weeks These trials were conducted separately with different patient populations and protocols
US$ 27.00
US$ 22.00
US$ 25.32
